سعر إيمباكوزا تريو إكس آر 25/5/1000 مجم 2024

Extended-release film-coated tablets; Egyptian directories list as Empacoza trio XR 25/5/1000 mg 30 FCT.

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (US label for equivalent formulation).Population: Adults with type 2 diabetesDailyMed (U.S. NLM)

• Common: urinary tract infection, genital mycotic infection, increased urination, thirst, nasopharyngitis; with metformin also GI upset (diarrhea, nausea). Laboratory: increased LDL-C, increased hematocrit (US labels).International label, equivalent formulation · DailyMed (U.S. NLM)

• Severe renal impairment, end-stage renal disease, or dialysis; acute or chronic metabolic acidosis including diabetic ketoacidosis; hypersensitivity to empagliflozin, metformin (and linagliptin if present) or any component (US Synjardy/Trijardy class).International label, equivalent formulation · DailyMed (U.S. NLM)

• Ketoacidosis (including euglycemic), volume depletion, urosepsis/pyelonephritis, genital mycotic infections, hypoglycemia with insulin/sulfonylurea, necrotizing fasciitis of the perineum (Fournier gangrene) reported with SGLT2 inhibitors (US labels).International label, equivalent formulation · DailyMed (U.S. NLM)
• Lactic acidosis risk with metformin (boxed warning on US Synjardy/Trijardy): higher risk with renal impairment, hypoxia, alcohol, contrast, hepatic disease; discontinue if suspected.International label, equivalent formulation · DailyMed (U.S. NLM)
• DPP-4 inhibitors including linagliptin: postmarketing reports of acute pancreatitis and severe joint pain; discontinue if pancreatitis suspected.International label, equivalent formulation · DailyMed (U.S. NLM)

• Insulin or insulin secretagogues (e.g. sulfonylureas)MajorIncreased risk of hypoglycemia; consider lower dose of insulin/secretagogue when coadministered.DailyMed (U.S. NLM)
• Iodinated contrast / alcohol / carbonic anhydrase inhibitorsMajorIncreases metformin lactic acidosis risk; withhold metformin around iodinated contrast per US label renal criteria; avoid excessive alcohol.DailyMed (U.S. NLM)

• US labels advise against use in second/third trimester based on animal data showing adverse renal effects of SGLT2 inhibitors; counsel and use alternative therapy when pregnancy recognized.International label, equivalent formulation · DailyMed (U.S. NLM)
• Not recommended while breastfeeding (US labels: risk of serious adverse reactions in breastfed infant from SGLT2/metformin exposure).International label, equivalent formulation · DailyMed (U.S. NLM)

• Empagliflozin: Inhibits SGLT2 in the proximal renal tubule, reducing renal reabsorption of filtered glucose and lowering the renal threshold for glucose, thereby increasing urinary glucose excretion (US label).
• Linagliptin: Inhibits DPP-4, increasing incretin (GLP-1/GIP) levels which enhance glucose-dependent insulin secretion.
• Metformin: Decreases hepatic glucose production, decreases intestinal glucose absorption and improves insulin sensitivity by increasing peripheral glucose uptake and utilization; insulin secretion remains unchanged (US label).